Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation

Journal of Biotechnology

Volumn 240, Issue , 2016, Pages 48-60

  Razaghi, Ali ^a   Owens, Leigh ^a   Heimann, Kirsten ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Actimmune; Biopharmaceutical; Cancer immunotherapy; Glycosylation; Interferon gamma; Protein expression purification

Indexed keywords

ANTIBIOTICS; BIOACTIVITY; DISEASES; ESCHERICHIA COLI; GLYCOPROTEINS; GLYCOSYLATION; MAMMALS; PRODUCTION PLATFORMS; PROTEINS; PURIFICATION;

ACTIMMUNE; BIOPHARMACEUTICAL; CANCER IMMUNOTHERAPY; INTERFERON-GAMMA; PROTEIN EXPRESSIONS;

INTERFERONS;

GAMMA INTERFERON; GAMMA1B INTERFERON; RECOMBINANT GAMMA INTERFERON; IFNG PROTEIN, HUMAN; RECOMBINANT PROTEIN;

BIOLOGICAL ACTIVITY; CANCER IMMUNOTHERAPY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG PURIFICATION; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; GENE THERAPY; GENOMICS; GLYCOSYLATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; ANIMAL; BIOSYNTHESIS; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASMS;

ANIMALS; ESCHERICHIA COLI; GENETIC THERAPY; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 84993960651     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2016.10.022     Document Type: Review

References (140)

1. Alberts, D.S., Marth, C., Alvarez, R.D., Johnson, G., Bidzinski, M., Kardatzke, D.R., Bradford, W.Z., Loutit, J., Kirn, D.H., Clouser, M.C., Markman, M., Consortium, G.C.T., Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol. Oncol. 109 (2008), 174–181, 10.1016/j.ygyno.2008.01.005.
2. Alfa, M.J., Dembinski, J.J., Jay, F.T., Production of monoclonal antibodies against recombinant human interferon-gamma: screening of hybridomas without purified antigen. Hybridoma 6 (1987), 509–520, 10.1089/hyb.1987.6.509.
3. Ank, N., West, H., Bartholdy, C., Eriksson, K., Thomsen, A.R., Paludan, S.R., Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80 (2006), 4501–4509, 10.1128/JVI.80.9.4501-4509.2006.
4. Arakawa, T., Alton, N.K., Hsu, Y.R., Preparation and characterization of recombinant DNA-derived human interferon-gamma. J. Biol. Chem. 260 (1985), 14435–14439.
5. Arbabi, M., Sanati, M.H., Hosseini, S., Deldar, A., Maghsoudi, N., Cloning and expression of human gamma-interferon on cDNA in E coli. Iran. J. Biotechnol. 1 (2003), 87–94.
6. Armstrong-James, D., Teo, I.A., Shrivastava, S., Petrou, M.A., Taube, D., Dorling, A., Shaunak, S., Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am. J. Transplant. 10 (2010), 1796–1803, 10.1111/j.1600-6143.2010.03094.x.
7. Arora, D., Khanna, N., Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies. J. Biotechnol. 52 (1996), 127–133, 10.1016/S0168-1656(96)01636-7.
8. Averhoff, F.M., Glass, N., Holtzman, D., Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin. Infect. Dis. 55:Suppl. 1 (2012), S10–15, 10.1093/cid/cis361.
9. Babaeipour, V., Shojaosadati, S.A., Robatjazi, S.M., Khalilzadeh, R., Maghsoudi, N., Over-production of human interferon-γ by HCDC of recombinant Escherichia coli. Process Biochem. 42 (2007), 112–117, 10.1016/j.procbio.2006.07.009.
10. Babaeipour, V., Shojaosadati, S., Khalilzadeh, R., Maghsoudi, N., Farnoud, A., Enhancement of human γ-interferon production in recombinant E. coli using batch cultivation. Appl. Biochem. Biotechnol. 160 (2010), 2366–2376, 10.1007/s12010-009-8718-5.
11. Babaeipour, V., Shojaosadati, S.A., Maghsoudi, N., Maximizing production of human interferon-gamma in HCDC of recombinant E. coli. Iran. J. Pharm. Res 12 (2013), 563–572.
12. Bach, E.A., Aguet, M., Schreiber, R.D., The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15 (1997), 563–591, 10.1146/annurev.immunol.15.1.563.
13. Bagis, H., Aktoprakligil, D., Gunes, C., Arat, S., Akkoc, T., Cetinkaya, G., Kankavi, O., Taskin, A., Arslan, K., Dundar, M., Tsoncheva, V., Ivanov, I., Expression of biologically active human interferon gamma in the milk of transgenic mice under the control of the murine whey acidic protein gene promoter. Biochem. Genet. 49 (2011), 251–257, 10.1007/s10528-010-9403-7.
14. Balderas Hernández, V., Paz Maldonado, L.T., Medina Rivero, E., Barba de la Rosa, A., Ordoñez Acevedo, L., León Rodríguez, A., Optimization of human interferon gamma production in Escherichia coli by response surface methodology. Biotechnol. Bioproc. E 13 (2008), 7–13, 10.1007/s12257-007-0126-5.
15. Baldridge, M.T., King, K.Y., Goodell, M.A., Inflammatory signals regulate hematopoietic stem cells. Trends Immunol. 32 (2011), 57–65, 10.1016/j.it.2010.12.003.
16. Beilharz, M.W., Therapeutic potential for orally administered type 1 interferons. Pharm. Sci. Technol. Today 3 (2000), 193–197, 10.1016/S1461-5347(00)00264-9.
17. Bocci, V., Pacini, A., Pessina, G.P., Paulesu, L., Muscettola, M., Lunghetti, G., Catabolic sites of human interferon-gamma. J. Gen. Virol. 66:Pt 4 (1985), 887–891, 10.1099/0022-1317-66-4-887.
18. Borden, E.C., Sen, G.C., Uze, G., Silverman, R.H., Ransohoff, R.M., Foster, G.R., Stark, G.R., Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6 (2007), 975–990, 10.1038/nrd2422.
19. Bouros, D., Antoniou, K.M., Tzouvelekis, A., Siafakas, N.M., Interferon-γ1b for the treatment of idiopathic pulmonary fibrosis. Expert Opin. Biol. Ther. 6 (2006), 1051–1060, 10.1517/14712598.6.10.1051.
20. Cereghino, J.L., Cregg, J.M., Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 24 (2000), 45–66, 10.1111/j.1574-6976.2000.tb00532.x.
21. Chen, T.L., Lin, Y.L., Lee, Y.L., Yang, N.S., Chan, M.T., Expression of bioactive human interferon-gamma in transgenic rice cell suspension cultures. Transgenic Res. 13 (2004), 499–510, 10.1007/s11248-004-2376-8.
22. Chen, W.S., Villaflores, O.B., Jinn, T.R., Chan, M.T., Chang, Y.C., Wu, T.Y., Expression of recombinant human interferon-gamma with antiviral activity in the bi-cistronic baculovirus-insect/larval system. Biosci. Biotechnol. Biochem. 75 (2011), 1342–1348, 10.1271/bbb.110107.
23. Chevillard, C., Henri, S., Stefani, F., Parzy, D., Dessein, A., Two new polymorphisms in the human interferon gamma (IFN-gamma) promoter. Eur. J. Immunogenet. 29 (2002), 53–56, 10.1046/j.0960-7420.2001.00281.x.
24. Choi, J.H., Keum, K.C., Lee, S.Y., Production of recombinant proteins by high cell density culture of Escherichia coli. Chem. Eng. Sci. 61 (2006), 876–885, 10.1016/j.ces.2005.03.031.
25. Chung, B.K., Yusufi, F.N., Mariati, Yang, Y., Lee, D.Y., Enhanced expression of codon optimized interferon gamma in CHO cells. J. Biotechnol. 167 (2013), 326–333, 10.1016/j.jbiotec.2013.07.011.
26. Crisafulli, S., Pandya, Y., Moolchan, K., Lavoie, T., Interferon gamma: activity and ELISA detection comparisons. Biotechniques 45 (2008), 101–102, 10.2144/000112943.
27. Dalgard, O., Bjoro, K., Hellum, K.B., Myrvang, B., Ritland, S., Skaug, K., Raknerud, N., Bell, H., Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40 (2004), 1260–1265, 10.1002/hep.20467.
28. Davoudi, N., Hemmati, A., Khodayari, Z., Adeli, A., Hemayatkar, M., Cloning and expression of human IFN-γ in Leishmania tarentolae. World J. Microbiol. Biotechnol. 27 (2011), 1893–1899, 10.1007/s11274-010-0648-4.
29. Derynck, R., Singh, A., Goeddel, D.V., Expression of the human interferon-gamma cDNA in yeast. Nucleic Acids Res. 11 (1983), 1819–1837, 10.1093/nar/11.6.1819.
30. Detjen, K.M., Farwig, K., Welzel, M., Wiedenmann, B., Rosewicz, S., Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 49 (2001), 251–262 10.1136%2Fgut.49.2.251.
31. Dummer, R., Hassel, J.C., Fellenberg, F., Eichmuller, S., Maier, T., Slos, P., Acres, B., Bleuzen, P., Bataille, V., Squiban, P., Burg, G., Urosevic, M., Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104 (2004), 1631–1638, 10.1182/blood-2004-01-0360.
32. Dunn, G.P., Koebel, C.M., Schreiber, R.D., Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 (2006), 836–848, 10.1038/nri1961.
33. Ealick, S.E., Cook, W.J., Vijay-Kumar, S., Carson, M., Nagabhushan, T.L., Trotta, P.P., Bugg, C.E., Three-dimensional structure of recombinant human interferon-gamma. Science 252 (1991), 698–702, 10.1126/science.1902591.
34. Ebrahimi, N., Memari, H.R., Ebrahimi, M.A., Ardakani, M.R., Cloning, transformation and expression of human gamma interferon gene in tomato (Lycopersicon Esculentum Mill.). Biotechnol. Biotechnol. Equip. 26 (2012), 2925–2929, 10.5504/bbeq.2012.0004.
35. Eggermont, A.M., Schraffordt Koops, H., Lienard, D., Kroon, B.B., van Geel, A.N., Hoekstra, H.J., Lejeune, F.J., Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol. 14 (1996), 2653–2665.
36. Farrar, M.A., Schreiber, R.D., The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11 (1993), 571–611, 10.1146/annurev.iy.11.040193.003035.
37. Fensterl, V., Sen, G.C., Interferons and viral infections. Biofactors 35 (2009), 14–20, 10.1002/biof.6.
38. Frucht, D.M., Fukao, T., Bogdan, C., Schindler, H., O'Shea, J.J., Koyasu, S., IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 22 (2001), 556–560, 10.1016/S1471-4906(01)02005-1.
39. Geng, X., Bai, Q., Zhang, Y., Li, X., Wu, D., Refolding and purification of interferon-gamma in industry by hydrophobic interaction chromatography. J. Biotechnol. 113 (2004), 137–149, 10.1016/j.jbiotec.2004.06.006.
40. Giannopoulos, A., Constantinides, C., Fokaeas, E., Stravodimos, C., Giannopoulou, M., Kyroudi, A., Gounaris, A., The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin. Cancer Res. 9 (2003), 5550–5558.
41. Gleave, M.E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L.H., Moore, M.J., Paton, V., Bajamonde, A., Bell, D., Ernst, S., Ramsey, E., Chin, J., Morales, A., Martins, H., Sanders, C., Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N. Engl. J. Med. 338 (1998), 1265–1271, 10.1056/NEJM199804303381804.
42. Gohil, K., Huge growth seen in hepatitis C market. P T, 39, 2014 517–517.
43. Gray, P.W., Leung, D.W., Pennica, D., Yelverton, E., Najarian, R., Simonsen, C.C., Derynck, R., Sherwood, P.J., Wallace, D.M., Berger, S.L., Levinson, A.D., Goeddel, D.V., Expression of human immune interferon cDNA in E. coli and monkey cells. Nature 295 (1982), 503–508, 10.1038/295503a0.
44. Guan, Y.-X., Pan, H.-X., Gao, Y.-G., Yao, S.-J., Cho, M.-G., Refolding and purification of recombinant human interferon-γ expressed as inclusion bodies in Escherichia coli using size exclusion chromatography. Biotechnol. Bioproc. E 10 (2005), 122–127, 10.1007/bf02932581.
45. Guan, Y.-Q., Zheng, Z., Liang, L., Li, Z., Zhang, L., Du, J., Liu, J.-M., The apoptosis of OVCAR-3 induced by TNF-α plus IFN-γ co-immobilized polylactic acid copolymers. J. Mater. Chem., 22, 2012, 14746, 10.1039/c2jm31972a.
46. Haelewyn, J., De Ley, M., A rapid single-step purification method for human interferon-gamma from isolated Escherichia coli inclusion bodies. Biochem. Mol. Biol. Int. 37 (1995), 1163–1171.
47. Hawkyard, S., James, K., Prescott, S., Jackson, A.M., Ritchie, A.W., Smyth, J.F., Chisholm, G.D., The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J. Urol. 145 (1991), 1078–1081.
48. Haynes, J., Weissman, C., Constitutive, long-term production of human interferons by hamster cells contalning multiple copies of a cloned interferon gene. Nucleic Acids Res. 11 (1983), 687–706, 10.1093/nar/11.3.687.
49. Honda, S., Asano, T., Kajio, T., Nakagawa, S., Ikeyama, S., Ichimori, Y., Sugino, H., Nara, K., Kakinuma, A., Kung, H.F., Differential purification by immunoaffinity chromatography of two carboxy-terminal portion-deleted derivatives of recombinant human interferon-gamma from Escherichia coli. J. Interferon Res. 7 (1987), 145–154, 10.1089/jir.1987.7.145.
50. Hooker, A., James, D., The glycosylation heterogeneity of recombinant human IFN-gamma. J. Interferon Cytokine Res. 18 (1998), 287–295, 10.1089/jir.1998.18.287.
51. Hu, X., Ivashkiv, L.B., Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31 (2009), 539–550, 10.1016/j.immuni.2009.09.002.
52. Huang, S.-K., Jin, J.-Y., Guan, Y.-X., Yao, Z., Cao, K., Yao, S.-J., Refolding of recombinant human interferon gamma inclusion bodies in vitro assisted by colloidal thermo-sensitive poly(N-isopropylacrylamide) brushes grafted onto the surface of uniform polystyrene cores. Biochem. Eng. J. 74 (2013), 20–26, 10.1016/j.bej.2013.02.015.
53. James, D.C., Freedman, R.B., Hoare, M., Ogonah, O.W., Rooney, B.C., Larionov, O.A., Dobrovolsky, V.N., Lagutin, O.V., Jenkins, N., N-glycosylation of recombinant human interferon-gamma produced in different animal expression systems. Biotechnology (N.Y.) 13 (1995), 592–596, 10.1038/nbt0695-592.
54. Janice, A.C., Patkar, A., McDonagh, G., Sinclair, A., Lucy, P., Modeling bioprocess cost: economic benefits of expression technology based on Pseudomonas fluorescens. Bioprocess Int. 8 (2010), 62–70.
55. Jin, T., Guan, Y.X., Yao, S.J., Lin, D.Q., Cho, M.G., On-column refolding of recombinant human interferon-gamma inclusion bodies by expanded bed adsorption chromatography. Biotechnol. Bioeng. 93 (2006), 755–760, 10.1002/bit.20763.
56. Jonasch, E., Haluska, F.G., Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6 (2001), 34–55, 10.1634/theoncologist.6-1-34.
57. Kelker, H.C., Yip, Y.K., Anderson, P., Vilcek, J., Effects of glycosidase treatment on the physicochemical properties and biological activity of human interferon-gamma. J. Biol. Chem. 258 (1983), 8010–8013.
58. Khalilzadeh, R., Shojaosadati, S.A., Bahrami, A., Maghsoudi, N., Over-expression of recombinant human interferon-gamma in high cell density fermentation of Escherichia coli. Biotechnol. Lett. 25 (2003), 1989–1992, 10.1023/B:BILE.0000004390.98648.25.
59. Khalilzadeh, R., Shojaosadati, S.A., Maghsoudi, N., Mohammadian-Mosaabadi, J., Mohammadi, M.R., Bahrami, A., Maleksabet, N., Nassiri-Khalilli, M.A., Ebrahimi, M., Naderimanesh, H., Process development for production of recombinant human interferon-gamma expressed in Escherichia coli. J. Ind. Microbiol. Biotechnol. 31 (2004), 63–69, 10.1007/s10295-004-0117-x.
60. Kim, J.Y., Kim, Y.G., Lee, G.M., CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl. Microbiol. Biotechnol. 93 (2012), 917–930, 10.1007/s00253-011-3758-5.
61. Koh, G.C., Limmathurotsakul, D., Gamma interferon supplementation for melioidosis. Antimicrob. Agents Chemother. 54 (2010), 4520–4521, 10.1128/AAC.00805-10.
62. Kortylewski, M., Komyod, W., Kauffmann, M.E., Bosserhoff, A., Heinrich, P.C., Behrmann, I., Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J. Invest. Dermatol. 122 (2004), 414–422, 10.1046/j.0022-202X.2004.22237.x.
63. Lagutin, O.V., Dobrovolsky, V.N., Vinogradova, T.V., Kyndiakov, B.N., Khodarovich, Y.M., Jenkins, N., James, D., Markham, N., Larionov, O.A., Efficient human IFN-gamma expression in the mammary gland of transgenic mice. J. Interferon Cytokine Res. 19 (1999), 137–144, 10.1089/107999099314289.
64. Lee, S., Choi, J., Lee, S., Secretory production of therapeutic proteins in Escherichia coli. Smales, C.M., James, D., (eds.) Therapeutic Proteins, 2005, Humana Press, 31–41.
65. Leister, P., Tileva, M., Krachmarova, E., Nacheva, G., Expression of human interferon-gamma gene in human tissue culture cells. Biotechnol. Biotechnol. Equip. 27 (2014), 3573–3576, 10.5504/bbeq.2012.0128.
66. Li, P., Du, Q., Cao, Z., Guo, Z., Evankovich, J., Yan, W., Chang, Y., Shao, L., Stolz, D.B., Tsung, A., Geller, D.A., Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett. 314 (2012), 213–222, 10.1016/j.canlet.2011.09.031.
67. Lienard, D., Eggermont, A.M., Kroon, B.B., Schraffordt Koops, H., Lejeune, F.J., Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin. Surg. Oncol. 14 (1998), 202–209.
68. Lundell, D.L., Narula, S.K., Structural elements required for receptor recognition of human interferon-gamma. Pharmacol. Ther. 64 (1994), 1–21, 10.1016/0163-7258(94)90031-0.
69. Lv, H., Zhang, H., Wu, J., Guan, Y., Effect of plasmid-mediated stable interferon-gamma expression on proliferation and cell death in the SKOV-3 human ovarian cancer cell line. Immunopharmacol. Immunotoxicol. 33 (2011), 498–503, 10.3109/08923973.2010.543685.
70. Malek Sabet, N., Masoumian, M.R., Nasiri-Khalili, M.A., Maghsoudi, N., Sami, H., Saeedinia, A., Mohammadi, R., The structural characterization of recombinant human interferon gamma. J. Biol. Sci. 8 (2008), 1087–1091, 10.3923/jbs.2008.1087.1091.
71. Marciano, B.E., Wesley, R., De Carlo, E.S., Anderson, V.L., Barnhart, L.A., Darnell, D., Malech, H.L., Gallin, J.I., Holland, S.M., Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin. Infect. Dis. 39 (2004), 692–699, 10.1086/422993.
72. Marth, C., Windbichler, G.H., Hausmaninger, H., Petru, E., Estermann, K., Pelzer, A., Mueller-Holzner, E., Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 16 (2006), 1522–1528, 10.1111/j.1525-1438.2006.00622.x.
73. Maylin, S., Martinot-Peignoux, M., Ripault, M.P., Moucari, R., Cardoso, A.C., Boyer, N., Giuily, N., Castelnau, C., Pouteau, M., Asselah, T., Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int. 29 (2009), 511–517, 10.1111/j.1478-3231.2008.01918.x.
74. McClain, D.A., Increasing IFN-Gamma Productivity in CHO Cells Through CDK Inhibition. 2010, Dept. of Chemical Engineering. Massachusetts Institute of Technology, MITlibraries, Boston p. 194.
75. Meager, A., The Interferons: Characterization and Application. 2006, Wiley-Blackwell.
76. Mikulecky, P., Zahradnik, J., Kolenko, P., Cerny, J., Charnavets, T., Kolarova, L., Necasova, I., Pham, P.N., Schneider, B., Crystal structure of human interferon-gamma receptor 2 reveals the structural basis for receptor specificity. Acta Crystallogr. D Struct. Biol. 72 (2016), 1017–1025, 10.1107/S2059798316012237.
77. Miller, C.H., Maher, S.G., Young, H.A., Clinical use of interferon-gamma. Ann. N. Y. Acad. Sci. 1182 (2009), 69–79, 10.1111/j.1749-6632.2009.05069.x.
78. Mironova, R., Niwa, T., Dimitrova, R., Boyanova, M., Ivanov, I., Glycation and post-translational processing of human interferon-gamma expressed in Escherichia coli. J. Biol. Chem. 278 (2003), 51068–51074, 10.1074/jbc.M307470200.
79. Miyakawa, N., Nishikawa, M., Takahashi, Y., Ando, M., Misaka, M., Watanabe, Y., Takakura, Y., Prolonged circulation half-life of interferon gamma activity by gene delivery of interferon gamma-serum albumin fusion protein in mice. J. Pharm. Sci. 100 (2011), 2350–2357, 10.1002/jps.22473.
80. Miyata, K., Yamamoto, Y., Ueda, M., Kawade, Y., Matsumoto, K., Kubota, I., Purification of natural human interferon-gamma by antibody affinity chromatography: analysis of constituent protein species in the dimers. J. Biochem. 99 (1986), 1681–1688.
81. Mohammadian-Mosaabadi, J., Naderi-Manesh, H., Maghsoudi, N., Nassiri-Khalili, M.A., Masoumian, M.R., Malek-Sabet, N., Improving purification of recombinant human interferon gamma expressed in Escherichia coli; effect of removal of impurity on the process yield. Protein Expr. Purif. 51 (2007), 147–156, 10.1016/j.pep.2006.07.002.
82. Mory, Y., Ben-Barak, J., Segev, D., Cohen, B., Novick, D., Fischer, D.G., Rubinstein, M., Kargman, S., Zilberstein, A., Vigneron, M., et al. Efficient constitutive production of human IFN-gamma in Chinese hamster ovary cells. DNA 5 (1986), 181–193, 10.1089/dna.1986.5.181.
83. Muir, A.J., Sylvestre, P.B., Rockey, D.C., Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J. Viral Hepat. 13 (2006), 322–328, 10.1111/j.1365-2893.2005.00689.x.
84. Nacheva, G., Todorova, K., Boyanova, M., Berzal-Herranz, A., Karshikoff, A., Ivanov, I., Human interferon gamma: significance of the C-terminal flexible domain for its biological activity. Arch. Biochem. Biophys. 413 (2003), 91–98, 10.1016/S0003-9861(03)00113-9.
85. Nakajima, T., Tsunoda, S., Nakada, S., Nagata, S., Oda, K., Hyperproduction of human interferon gamma by rat cells maintained in low-serum medium using the fibronectin gene promoter. J. Biochem. 112 (1992), 590–597.
86. Nathan, C.F., Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158 (1983), 670–689, 10.1084/jem.158.3.670.
87. Ni, C., Wu, P., Zhu, X., Ye, J., Zhang, Z., Chen, Z., Zhang, T., Zhang, T., Wang, K., Wu, D., Qiu, F., Huang, J., IFN-gamma selectively exerts pro-apoptotic effects on tumor-initiating label-retaining colon cancer cells. Cancer Lett. 336 (2013), 174–184, 10.1016/j.canlet.2013.04.029.
88. Noone, C., Kihm, A., English, K., O'Dea, S., Mahon, B.P., IFN-gamma stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev. 22 (2013), 3003–3014, 10.1089/scd.2013.0028.
89. Novick, D., Eshhar, Z., Fischer, D.G., Friedlander, J., Rubinstein, M., Monoclonal antibodies to human interferon-gamma: production, affinity purification and radioimmunoassay. EMBO J. 2 (1983), 1527–1530 PMC555317.
90. Pai, M., Riley, L.W., Colford, J.M. Jr., Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4 (2004), 761–776, 10.1016/S1473-3099(04)01206-X.
91. Panahi, Y., Davoudi, S.M., Madanchi, N., Abolhasani, E., Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis. Clin. Exp. Med. 12 (2012), 241–245, 10.1007/s10238-011-0164-3.
92. Perez, L., Vega, J., Chuay, C., Menendez, A., Ubieta, R., Montero, M., Padron, G., Silva, A., Santizo, C., Besada, V., et al. Production and characterization of human gamma interferon from Escherichia coli. Appl. Microbiol. Biotechnol. 33 (1990), 429–434, 10.1007/bf00176659.
93. Petrov, S., Nacheva, G., Ivanov, I., Purification and refolding of recombinant human interferon-gamma in urea-ammonium chloride solution. Protein Expr. Purif. 73 (2010), 70–73, 10.1016/j.pep.2010.03.026.
94. Prabhu, A.A., Veeranki, V.D., Dsilva, S.J., Improving the production of human interferon gamma (hIFN-γ) in Pichia pastoris cell factory: an approach of cell level. Process. Biochem., 2016, 10.1016/j.procbio.2016.02.007.
95. Qi, Z., Nie, P., Secombes, C.J., Zou, J., Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs. J. Immunol. 184 (2010), 5038–5046, 10.4049/jimmunol.0903374.
96. Rader, R.A., FDA biopharmaceutical product approvals and trends in 2012. BioProcess Int. 11 (2013), 18–27.
97. Raghu, G., Brown, K.K., Bradford, W.Z., Starko, K., Noble, P.W., Schwartz, D.A., King, T.E. Jr., G. Idiopathic Pulmonary Fibrosis Study, A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 350 (2004), 125–133, 10.1056/NEJMoa030511.
98. Razaghi, A., Huerlimann, R., Owens, L., Heimann, K., Increased expression and secretion of recombinant hIFNγ through amino acid starvation-induced selective pressure on the adjacent HIS4 gene in Pichia pastoris. Acta Fac. Pharm. Univ. Comen. 62 (2015), 43–50, 10.1515/afpuc-2015-0031.
99. Razaghi, A., Tan, E., Lua, L., Owens, L., Karthikeyan, O.P., Heimann, K., Is Pichia pastoris a realistic platform for industrial production of recombinant human interferon gamma?. Biologicals, 2016, 10.1016/j.biologicals.2016.09.015.
100. Reddy, P.K., Reddy, S.G., Narala, V.R., Majee, S.S., Konda, S., Gunwar, S., Reddy, R.C., Increased yield of high purity recombinant human interferon-gamma utilizing reversed phase column chromatography. Protein Expr. Purif. 52 (2007), 123–130, 10.1016/j.pep.2006.08.013.
101. Rinderknecht, E., O'Connor, B.H., Rodriguez, H., Natural human interferon-gamma: complete amino acid sequence and determination of sites of glycosylation. J. Biol. Chem. 259 (1984), 6790–6797.
102. Rodrigues, M.E., Costa, A.R., Henriques, M., Cunnah, P., Melton, D.W., Azeredo, J., Oliveira, R., Advances and drawbacks of the adaptation to Serum-Free culture of CHO-K1 cells for monoclonal antibody production. Appl. Biochem. Biotechnol. 169 (2013), 1279–1291, 10.1007/s12010-012-0068-z.
103. Rojas Contreras, J.A., Pedraza-Reyes, M., Ordonez, L.G., Estrada, N.U., Barba de la Rosa, A.P., De Leon-Rodriguez, A., Replicative and integrative plasmids for production of human interferon gamma in Bacillus subtilis. Plasmid 64 (2010), 170–176, 10.1016/j.plasmid.2010.07.003.
104. Samuel, C.E., Antiviral actions of interferons. Clin. Microbiol. Rev. 14 (2001), 778–809, 10.1128/CMR.14.4.778-809.2001.
105. Santín Cerezales, M., Benítez, J.D., Diagnosis of tuberculosis infection using interferon-γ-based assays. Enferm. Infecc. Microbiol. Clin. 29 (2011), 26–33, 10.1016/s0213-005x(11)70015-5.
106. Sareneva, T., Cantell, K., Pyhala, L., Pirhonen, J., Julkunen, I., Effect of carbohydrates on the pharmacokinetics of human interferon-gamma. J. Interferon Res. 13 (1993), 267–269, 10.1089/jir.1993.13.267.
107. Sareneva, T., Pirhonen, J., Cantell, K., Julkunen, I., N-glycosylation of human interferon-γ: glycans at Asn-25 are critical for protease resistance. Biochem. J. 308 (1995), 9–14, 10.1042/bj3080009.
108. Sareneva, T., Mortz, E., Tolo, H., Roepstorff, P., Julkunen, I., Biosynthesis and N-glycosylation of human interferon-gamma. Asn25 and Asn97 differ markedly in how efficiently they are glycosylated and in their oligosaccharide composition. Eur. J. Biochem. 242 (1996), 191–200, 10.1111/j.1432-1033.1996.0191r.x.
109. Scahill, S.J., Devos, R., Van der Heyden, J., Fiers, W., Expression and characterization of the product of a human immune interferon cDNA gene in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. U. S. A. 80 (1983), 4654–4658.
110. Schroder, K., Hertzog, P.J., Ravasi, T., Hume, D.A., Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75 (2004), 163–189, 10.1189/jlb.0603252.
111. Takaoka, A., Yanai, H., Interferon signalling network in innate defence. Cell. Microbiol. 8 (2006), 907–922, 10.1111/j.1462-5822.2006.00716.x.
112. Topalian, S.L., Wolchok, J.D., Chan, T.A., Mellman, I., Palucka, K., Banchereau, J., Rosenberg, S.A., Dane Wittrup, K., Immunotherapy: the path to win the war on cancer?. Cell 161 (2015), 185–186, 10.1016/j.cell.2015.03.045.
113. Tsiouris, S.J., Coetzee, D., Toro, P.L., Austin, J., Stein, Z., El-Sadr, W., Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J. Clin. Microbiol. 44 (2006), 2844–2850, 10.1128/JCM.02411-05.
114. Vadrot, N., Legrand, A., Nello, E., Bringuier, A.F., Guillot, R., Feldmann, G., Inducible nitric oxide synthase (iNOS) activity could be responsible for resistance or sensitivity to IFN-gamma-induced apoptosis in several human hepatoma cell lines. J. Interferon Cytokine Res. 26 (2006), 901–913, 10.1089/jir.2006.26.901.
115. Vaiphei, S.T., Pandey, G., Mukherjee, K.J., Kinetic studies of recombinant human interferon-gamma expression in continuous cultures of E. coli. J. Ind. Microbiol. Biotechnol. 36 (2009), 1453–1458, 10.1007/s10295-009-0632-x.
116. Vandenbroeck, K., Martens, E., D'Andrea, S., Billiau, A., Refolding and single-step purification of porcine interferon-gamma from Escherichia coli inclusion bodies. Conditions for reconstitution of dimeric IFN-gamma. Eur. J. Biochem. 215 (1993), 481–486, 10.1111/j.1432-1033.1993.tb18057.x.
117. Varedi, S., Shojaosadati, S., Babaeipour, V., Ghaemi, N., Physiological and morphological changes of recombinant E. coli during over-expression of human interferon-g in HCDC. Iran. J. Biotechnol. 4 (2006), 230–238.
118. Varki, A., Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 3 (1993), 97–130, 10.1093/glycob/3.2.97.
119. Vesenbeckh, S.M., Schonfeld, N., Mauch, H., Bergmann, T., Wagner, S., Bauer, T.T., Russmann, H., The use of interferon gamma release assays in the diagnosis of active tuberculosis. Tuberc. Res. Treat., 2012, 2012, 768723, 10.1155/2012/768723.
120. Vial, T., Descotes, J., Clinical toxicity of the interferons. Drug Saf. 10 (1994), 115–150, 10.2165/00002018-199410020-00003.
121. Vilcek, J., Novel interferons. Nat. Immunol. 4 (2003), 8–9, 10.1038/ni0103-8.
122. Vivo, C., Levy, F., Pilatte, Y., Fleury-Feith, J., Chretien, P., Monnet, I., Kheuang, L., Jaurand, M.C., Control of cell cycle progression in human mesothelioma cells treated with gamma interferon. Oncogene 20 (2001), 1085–1093, 10.1038/sj.onc.1204199.
123. Wall, L., Burke, F., Barton, C., Smyth, J., Balkwill, F., IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin. Cancer Res. 9 (2003), 2487–2496.
124. Walter, M.R., Windsor, W.T., Nagabhushan, T.L., Lundell, D.J., Lunn, C.A., Zauodny, P.J., Narula, S.K., Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Nature 376 (1995), 230–235, 10.1038/376230a0.
125. Wang, S., Xub, H., Dengb, Y., The antiproliferative activity of combination treatment of IFN-γ and doxorubicin on H22 cells: in vitro and in vivo. Cancer Ther., 9, 2009, 10.
126. Wang, D., Ren, H., Xu, J.W., Sun, P.D., Fang, X.D., Expression, purification and characterization of human interferon-gamma in Pichia pastoris. Mol. Med. Rep. 9 (2014), 715–719, 10.3892/mmr.2013.1812.
127. Waschutza, G., Li, V., Schafer, T., Schomburg, D., Villmann, C., Zakaria, H., Otto, B., Engineered disulfide bonds in recombinant human interferon-gamma: the impact of the N-terminal helix A and the AB-loop on protein stability. Protein Eng. 9 (1996), 905–912, 10.1093/protein/9.10.905.
128. Welander, C.E., Homesley, H.D., Reich, S.D., Levin, E.A., A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am. J. Clin. Oncol. 11 (1988), 465–469.
129. Wiesenfeld, M., O'Connell, M., Wieand, H., Gonchoroff, N., Donohue, J., Fitzgibbons, R. Jr., Krook, J., Mailliard, J., Gerstner, J., Pazdur, R., Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J. Clin. Oncol. 13 (1995), 2324–2329.
130. Windbichler, G.H., Hausmaninger, H., Stummvoll, W., Graf, A.H., Kainz, C., Lahodny, J., Denison, U., Muller-Holzner, E., Marth, C., Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 82 (2000), 1138–1144, 10.1054/bjoc.1999.1053.
131. Xie, F.J., Zhao, P., Zhang, Y.P., Liu, F.Y., Nie, X.L., Zhu, Y.H., Yu, X.M., Zheng, Q.Q., Mao, W.M., Lu, H.Y., Wei, H., Huang, W., Adenovirus-mediated interferon-gamma gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo. Anat. Rec. (Hoboken) 296 (2013), 604–610, 10.1002/ar.22661.
132. Yip, Y.K., Barrowclough, B.S., Urban, C., Vilcek, J., Purification of two subspecies of human gamma (immune) interferon. Proc. Natl. Acad. Sci. U. S. A. 79 (1982), 1820–1824, 10.1073/pnas.79.6.1820.
133. Younes, H.M., Amsden, B.G., Interferon-gamma therapy: evaluation of routes of administration and delivery systems. J. Pharm. Sci. 91 (2002), 2–17, 10.1002/jps.10007.
134. Yphantis, D.A., Arakawa, T., Sedimentation equilibrium measurements of recombinant DNA derived human interferon gamma. Biochemistry 26 (1987), 5422–5427, 10.1021/bi00391a031.
135. Zaidi, M.R., Merlino, G., The two faces of interferon-gamma in cancer. Clin. Cancer Res. 17 (2011), 6118–6124, 10.1158/1078-0432.CCR-11-0482.
136. Zhang, Z., Tong, K.T., Belew, M., Pettersson, T., Janson, J.C., Production, purification and characterization of recombinant human interferon gamma. J. Chromatogr. 604 (1992), 143–155, 10.1016/0021-9673(92)85539-6.
137. Zhao, P., Zhu, Y.H., Wu, J.X., Liu, R.Y., Zhu, X.Y., Xiao, X., Li, H.L., Huang, B.J., Xie, F.J., Chen, J.M., Ke, M.L., Huang, W., Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth. Life Sci. 81 (2007), 695–701, 10.1016/j.lfs.2007.05.028.
138. Zhong, X., Somers, W., Recent Advances in Glycosylation Modifications in the Context of Therapeutic Glycoproteins. 2012, INTECH Open Access Publisher, Shanghai.
139. Zuo, Y., Wu, J., Xu, Z., Yang, S., Yan, H., Tan, L., Meng, X., Ying, X., Liu, R., Kang, T., Huang, W., Minicircle-oriP-IFNgamma: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma. PLoS One, 6, 2011, e19407, 10.1371/journal.pone.0019407.
140. Zwerling, A., van den Hof, S., Scholten, J., Cobelens, F., Menzies, D., Pai, M., Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 67 (2012), 62–70, 10.1136/thx.2010.143180.